1. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

   • Paul R. Hutson
   • Kurt Oettel
   • George Wilding

   Original Article 09 October 2007 Pages: 373 - 377

   

2. The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel

   • Fumio Sakashita
   • Shinji Osada
   • Mitsuru Seishima

   Original Article 25 October 2007 Pages: 379 - 385

   

3. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates

   • Holly J. Meany
   • Elizabeth Fox
   • Frank M. Balis

   Original Article 12 October 2007 Pages: 387 - 392

   

4. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

   • Dominique Koensgen
   • Dirk Stengel
   • on behalf of the NOGGO (North-Eastern German Society of Gynecological Oncology) Study Group Ovarian Cancer

   Original Article 09 October 2007 Pages: 393 - 400

   

5. Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis

   • Teppei Matsui
   • Hidenari Nagai
   • Kazumasa Miki

   Original Article 12 October 2007 Pages: 401 - 406

   

6. Combination of all-trans retinoic acid and interferon-gamma upregulated p27^kip1 and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells

   • Ran Zhang
   • Naren L. Banik
   • Swapan K. Ray

   Original Article 25 October 2007 Pages: 407 - 416

   

7. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts

   • William C. Zamboni
   • Sandra Strychor
   • Julie L. Eiseman

   Original Article 24 October 2007 Pages: 417 - 426

   

8. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium

   • Aiko Tsuda
   • Junshin Fujiyama
   • Yasufumi Sawada

   Original Article 17 November 2007 Pages: 427 - 432

   

9. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

   • Katherine E. Warren
   • Cindy McCully
   • Frank M. Balis

   Original Article 25 October 2007 Pages: 433 - 437

   

10. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia

    • Lars Möllgård
    • Stefan Deneberg
    • Sören Lehmann

    Original Article 25 October 2007 Pages: 439 - 448

    

11. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors

    • Kostas Kalbakis
    • Periklis Pappas
    • Dimitris Mavroudis

    Original Article 25 October 2007 Pages: 449 - 456

    

12. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice

    • Jan H. Beumer
    • Julie L. Eiseman
    • Merrill J. Egorin

    Original Article 15 November 2007 Pages: 457 - 464

    

13. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer

    • Fumihiro Oshita
    • Kouzo Yamada
    • Kazumasa Noda

    Original Article 25 October 2007 Pages: 465 - 470

    

14. Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species

    • Inesa Levovich
    • Abraham Nudelman
    • Ada Rephaeli

    Original Article 21 November 2007 Pages: 471 - 482

    

15. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

    • Marisa A. Navo
    • Judith A. Smith
    • Lois M. Ramondetta

    Original Article 15 November 2007 Pages: 483 - 489

    

16. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells

    • Victor Adler
    • Wilbur Bowne
    • Matthew R. Pincus

    Original Article 08 December 2007 Pages: 491 - 498

    

17. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors

    • Marwan G. Fakih
    • Lakshmi Pendyala
    • Youcef M. Rustum

    Original Article 08 November 2007 Pages: 499 - 508

18. 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy

    • Huifei Cui
    • Jie Shen
    • Peng George Wang

    Original Article 16 November 2007 Pages: 509 - 515

    

19. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N ¹ , N ¹¹ diethylnorspermine

    • Suzanne Hector
    • Ramakumar Tummala
    • Lakshmi Pendyala

    Original Article 07 November 2007 Pages: 517 - 527

    

20. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients

    • Kimie Sai
    • Yoshiro Saito
    • Jun-ichi Sawada

    Original Article 08 November 2007 Pages: 529 - 537

    

21. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma

    • Yu-Hong Li
    • Feng-Hua Wang
    • You-Jian He

    Original Article 03 January 2008 Pages: 539 - 544

    

22. Influence of carboplatin infusion on osteosarcoma blood flow

    • Gene R. DiResta
    • Sean W. Aiken
    • John H. Healey

    Short Communication 12 October 2007 Pages: 545 - 549

    

23. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients

    • Kazuhiro Ozawa
    • Hironobu Minami
    • Hitoshi Sato

    Short Communication 07 December 2007 Pages: 551 - 557